This suggests that deletion of P32 inhibits the expression of mutant CHCHD2 and its downstream pathway activation, thereby reducing the toxic gain of function associated with the mutation and ameliorating the PD-associated phenotype. The gene discussed is CHCHD2; the disease is Parkinson disease.